[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457274":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"IgAN patients","Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney\u002Fgraft function Patients followed in the Nephrology Department of Strasbourg University Hospital.",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Sophie Ohlmann- Caillard, MD","CONTACT","03.88.11.67.68","sophie.ohlmann@chru-strasbourg.fr",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Service de néphrologie","RECRUITING","Strasbourg","France","FR",{"type":26,"coordinates":27},"Point",[28,29],7.74553,48.58392,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":7,"phoneExt":7,"email":7},"Sophie Caillard, MD",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100457274","study-of-the-link-between-complement-activation-and-iga-nephropathy-severity-100457274",false,"NCT05234463","Study of the Link Between Complement Activation and IgA Nephropathy Severity","ICONE","Inclusion Criteria:\n\n* Adult patients, male or female, with a biopsy proven IgA nephropathy.\n* Primitive and secondary forms can be included\n* Regardless of the date of diagnosis and the level of kidney function\n* With or without past of kidney transplantation\n* Followed in the Nephrology Department, Strasbourg University Hospital\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active or recent infectious or inflammatory syndrome (\\\u003C2 months), recent vaccination (\\\u003C2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (\\\u003C2 months), current treatment with complement inhibitors\n* Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)\n* Subject under safeguard of justice, guardianship or curatorship","ALL","18 Years",{"count":46,"type":47},400,"ESTIMATED","OBSERVATIONAL","ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.\n\nThe main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.",[51],"IgA Nephropathy Severity in Kidney Transplantation","2026-08-18",{"date":54,"type":55},"2026-08-19","ACTUAL",{"date":57,"type":55},"2022-05-09",{"date":59,"type":47},"2027-05-01",{"name":5,"class":6},1]